Clinical trials: Former Smoker
Smoking Cessation
Escape Smoke Project: Non-Intervention Non-Drug Multicenter Study on the Real-life Effectiveness of Smoking Cessation in General Practice in Denmark
Real life smoking cessation rates after 24 weeks non-intervention design. Approximately 40 General Practice (GP) centers with 800 smokers will participate.
- Trial name
- ESCAPE SMOKE (NCT01544621)
- Testing
- Smoking cessation
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- Pfizer
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objectives of the study are: To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell…
- Conditions
- Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT03088540
- Testing
- Pemetrexed, Paclitaxel, Gemcitabine
- Where
- 192 sites in Australia, Belarus and 22 more
- Volunteers
- 712 people
- Sponsor
- Regeneron Pharmaceuticals
Nicotine Addiction, Drug Addiction
Clinical Trial of Smoking Cessation Mobile Phone Program
The Sponsor is doing a research study to assess the effects of a smartphone program designed to help users smoke less and eventually quit. When participants join, their involvement in the core study will last 8 weeks.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT02656745
- Testing
- Mobile Smoking Cessation Solution
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Click Therapeutics, Inc.
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in…
- Trial name
- ASIA CHOICES (NCT00808015)
- Testing
- varenicline
- Where
- 97 sites in China, India and 2 more
- Volunteers
- 1,373 people
- Sponsor
- Pfizer
Smoking Cessation
Varenicline Observational Investigation In The Cessation of Smoking
The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support…
- Trial name
- CHOICES (NCT00669240)
- Testing
- Varenicline
- Where
- 52 sites in Belgium, Greece and 2 more
- Volunteers
- 567 people
- Sponsor
- Pfizer
Smoking Cessation
A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery
It is possible to offer smoking cessation treatment including varenicline to patients scheduled for elective surgery. This study will evaluate whether or not this will enable some patients to quit smoking for up to 4 weeks prior…
- Trial name
- NCT00889720
- Testing
- Varenicline
- Where
- 2 sites in France, Italy
- Volunteers
- 16 people
- Sponsor
- Pfizer
Respiratory Disorders
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
The purpose of this study is to test two different vaccine schedules to be used for administering the investigational NTHi Mcat vaccine that will be targeting patients with chronic obstructive pulmonary disease (COPD) to prevent…
- Trial name
- NCT03443427
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 8 sites in Canada, Germany and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking Cessation, Insurance Coverage
Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
This study is based on the hypothesis that access to smoking cessation treatment (SCT) reimbursement may significantly increase the number of successful quitters in a population of smokers motivated to quit by: 1) increasing the…
- Trial name
- ACCESSATION (NCT00818207)
- Testing
- Full Smoking Cessation Treatment Coverage (100%), No Smoking Cessation Treatment Coverage (0%)
- Where
- 56 sites in Canada
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Pfizer
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
This randomized parallel group study will assess the efficacy and safety of erlotinib [Tarceva], as monotherapy or intermittent dosing with docetaxel, in second-line setting in former-smoker male patients with advanced or…
- Trial name
- NCT01204697
- Testing
- docetaxel, erlotinib [Tarceva]
- Where
- 20 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Smoking Cessation
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment.
- Trial name
- NCT01244061
- Testing
- Varenicline
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 498 people
- Sponsor
- Pfizer
Lung Cancer
Airway Epithelium Gene Expression: AEGIS IDE
The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured.
- Trial name
- AEGIS IDE (NCT00746759)
- Testing
- Biomarker (not used as an intervention)
- Where
- 21 sites in United States
- Volunteers
- 1,331 people
- Sponsor
- Allegro Diagnostics, Corp.
Smoking
Clinical Study of Smoke-Break Liquid Cigarettes
The purpose of this study is to determine whether the Smoke-Break nicotine delivery device can help smokers quit smoking, while avoiding many of the side effects associated with other smoking cessation products.
- Trial name
- NCT00715871
- Testing
- Nicotine, Smoke-Break nicotine delivery device
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Smoke-Break, Inc.
Non-squamous Non-small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small…
- Trial name
- NCT02264990
- Testing
- Paclitaxel, Carboplatin, Cisplatin
- Where
- 140 sites in United States, Argentina and 18 more
- Volunteers
- 595 people
- Sponsor
- AbbVie
Smoking Cessation
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data…
- Trial name
- CATS (NCT01574703)
- Testing
- varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
- Where
- 134 sites in United States, Argentina and 14 more
- Volunteers
- 4,595 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lung Neoplasms, Pulmonary Disease, Chronic Obstructive
A Study of Smoking Cessation Patterns in Participants Undergoing Lung Surgery
The purpose of this study is to assess the current smoking status and smoking cessation attempts among smokers or recent smoking quitters during the perioperative period, to describe postoperative pulmonary complications (PPCs)…
- Trial name
- CHAMPION (NCT04313361)
- Testing
- No intervention
- Where
- 3 sites in China
- Volunteers
- 290 people
- Sponsor
- Johnson & Johnson (China) Investment Ltd.
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy.
- Trial name
- NCT02013206
- Testing
- erlotinib [Tarceva]
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
COPD, Asthma
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
This study will collect sputum samples from healthy smokers, COPD smokers and COPD ex-smokers to analyse biomarkers of inflammation
- Trial name
- NCT02490358
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Lung Cancer
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and…
- Trial name
- NCT00414960
- Testing
- Enzastaurin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company